Patient-derived xenograft models of BRCA-wildtype and CCNE1-amplified platinum-resistant ovarian cancer, which are associated with increased baseline activation of ATR/CHK1, demonstrated tumor reduction and a significant increase in OS when treated with the combination of PARPi and ATRi (185). The gene discussed is ATR; the disease is ovarian carcinoma.